Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are INELIGIBLE Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Has a known history of human immunodeficiency virus (HIV) (HIV / antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy Known human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy Known HIV-positive patients on combination antiretroviral therapy. Human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible A known history of human immunodeficiency virus (HIV) seropositivity; HIV-positive patients on combination antiretroviral therapy are ineligible Patients may not have known human immunodeficiency virus (HIV) infection; HIV-positive patients on combination antiretroviral therapy are ineligible Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients with active human immunodeficiency virus (HIV) or hepatitis C; (HIV-positive patients on combination antiretroviral therapy or hepatitis C-positive patients on antiviral therapy are ineligible) Patients with known prior human immunodeficiency virus (HIV)-positive status on combination antiretroviral therapy are ineligible; known prior HIV-positive patients with cluster of differentiation (CD)+ =< /mm^ are ineligible (HIV testing is not required as part of this study) Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions vemurafenib and cobimetinib COHORT : HORMONE RECEPTOR POSITIVE BREAST CANCER: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible COHORT : ENDOMETRIAL CANCER: HIV-positive patients on combination antiretroviral therapy are ineligible Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with meclizine. Human deficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV) seropositive patients with acceptable organ function who meet the patient selection criteria, and who are not on combination antiretroviral therapy, and whose absolute CD+ count is >= cells per cubic millimeter of blood, will be eligible; however, HIV positive patients on combination antiretroviral therapy will be ineligible, because of the potential for pharmacokinetic interactions with cabozantinib Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy Patients with known human immunodeficiency virus (HIV) on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV) positive patients with CD counts below OR who are not on a stable dose of antiretroviral therapy (for at least month prior to registration) are ineligible Known human immunodeficiency virus (HIV)-positive patients who are on combination antiretroviral therapy; (this is because of the potential for pharmacokinetic interactions with denosumab) Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided they have stable CD counts above Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible; HIV testing is not required, but patients must not be known to be HIV-positive Patients who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients with uncontrolled HIV despite combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients on combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible mCRPC EXPANSION COHORT: HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with vandetanib/metformin Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients with a known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy are ineligible for the initial first-in-man trial The subject is known to be positive for the human immunodeficiency virus (HIV) and is receiving antiretroviral therapies; subjects known to be HIV-positive who do not require antiretroviral therapy will be eligible if they meet other entry criteria HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral treatment are ineligible History of human immunodeficiency virus (HIV) or HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-infected patients should be receiving or willing to initiate an effective combination antiretroviral therapy (cART) regimen HIV-positive patients on combination antiretroviral therapy are ineligible because of unknown potential for interactions with cenersen. Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with lenvatinib Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible TUMOR BIOPSY SEQUENCING: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency (HIV)-positive participants on combination antiretroviral therapy are ineligible Has a known history of human immunodeficiency virus (HIV) (HIV / antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder \r\n* NOTE: HIV-positive patients taking combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible Human immunodeficiency virus (HIV) positive patients who are on combination antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patients CD count is below the institutional lower limit of normal Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible Patients who are human immunodeficiency virus (HIV) positive must be willing to comply with effective antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible HIV-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on CYPA modulating antiretroviral therapy are ineligible Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV and HIV testing is not otherwise required Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Confirmed human immunodeficiency virus (HIV) positive whether or not on antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral therapies are eligible for this study Human immunodeficiency virus (HIV)-positive patients or those on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV- positive patients who are not on combination antiretroviral therapy (cART) and have CD counts > are eligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patients with human immunodeficiency virus (HIV) whom are not receiving antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible; HIV testing is not required for study enrollment and optional Patients that are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy Patient is human immunodeficiency virus (HIV)-positive and is receiving combination antiretroviral therapy Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible HIV-positive patients on combination antiretroviral therapy. HIV-positive patients on combination antiretroviral therapy are ineligible Subjects who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are excluded from the study Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Known human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV; HIV testing is not otherwise required Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapies Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible HIV-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible